Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. 1976

I J Fidler, and D M Gersten, and M B Budmen

This report describes the selection and behavior of tumor cells resistant to cytolysis by syngeneic lymphocytes. Two B16 melanoma lines, F1 (low metastasis) and F10 (high metastasis), were cultured with lymphocytes from C57BL/6 mice immunized against B16. The selection procedure involved repeated exposure of the tumor cells to lymphocytes in vitro. After each interaction, the viable tumor cells were trpsinized, replated, and designated lines F1Lr-1 and F10Lr-1. The procedure was repeated five times, yielding lines F1Lr-6 and F10Lr-6, which resisted cytolysis by syngeneic lymphocytes. Mice were given s.c. or i.v. injections of cells from lines F1, F1Lr-6, F10, or F10Lr-6. Tumor growth patterns were the same for all four lines when the cells were injected s.c., however, the incidence of pulmonary metastases differed significantly after i.v. injection. Line F10 cells yielded more pulmonary metastases than an equal number of line F1 cells (p less than 0.01). F1Lr-6 cells yielded significantly fewer metastases than an equal number of lines F1 cells (p less than 0.01). A similar difference between F10Lr-6 and F10 cells was observed. The incidence of artificial metastases after i.v. injection of F10Lr-6 cells was similar to that for F1 cells. The quantitative organ distribution, arrest, and survival of i.v.-injected tumor cells were studied by using [125]-5-iodo-2'-deoxyuridinelabeled cells. There was a significantly greater number of cells from line F10, arrested and able to survive for 14 days in lungs, than cells from line F1. In contrast, cells from either line F1Lr-6 or F10Lr-6 had a lower incidence of arrest and survival than their lymphocyte-sensitive counterparts.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M

Related Publications

I J Fidler, and D M Gersten, and M B Budmen
January 1975, Archiv fur Geschwulstforschung,
I J Fidler, and D M Gersten, and M B Budmen
January 1976, Surgical forum,
I J Fidler, and D M Gersten, and M B Budmen
February 1975, Annals of the New York Academy of Sciences,
I J Fidler, and D M Gersten, and M B Budmen
August 1995, Immunological reviews,
I J Fidler, and D M Gersten, and M B Budmen
January 1974, Johns Hopkins medical journal. Supplement,
I J Fidler, and D M Gersten, and M B Budmen
September 1974, Journal of immunology (Baltimore, Md. : 1950),
I J Fidler, and D M Gersten, and M B Budmen
January 1977, Proceedings of the National Academy of Sciences of the United States of America,
I J Fidler, and D M Gersten, and M B Budmen
June 1979, Journal of the National Cancer Institute,
Copied contents to your clipboard!